Physician profile
Brian D Snoddy
NPI 1649355827
$3,757.52
in general payments reported to CMS, 2019-2025
27 companies · $525 in 2025
The $525 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $578 · 2020: $44.04 · 2021: $75.25 · 2022: $1,071 · 2023: $884 · 2024: $580 · 2025: $525.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,990.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,989.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $658.18 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $503.95 | 2019-2025 | Jardiance |
| Abbott Laboratories | $462.89 | 2019-2023 | Jeti, Jeti Peripheral Catheter |
| Pfizer INC. | $381.78 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $283.43 | 2019-2025 | Camzyos, Eliquis |
| Amgen INC. | $272.67 | 2019-2025 | Repatha, Repatha |
| Merck Sharp & Dohme LLC | $201.33 | 2021-2024 | Verquvo |
| Janssen Pharmaceuticals, INC | $162.23 | 2019-2023 | Xarelto |
| Sanofi-Aventis U.S. LLC | $147.54 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $135.42 | 2022-2025 | Farxiga, Lokelma |
| Organogenesis INC. | $117.51 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $74.03 | 2025 | |
| Lundbeck LLC | $49.08 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $39.61 | 2022-2024 | Opsumit, Uptravi |
| Regeneron Healthcare Solutions, INC. | $34.42 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biocompatibles, INC. | $30.45 | 2019 | |
| Amarin Pharma, INC. | $24.54 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $20.36 | 2024 | Arcalyst |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $20.21 | 2025 | Lifevest |
| Angiodynamics, INC. | $19.92 | 2019 | |
| Boston Scientific Corporation | $19.36 | 2024 | |
| Cardiovascular Systems INC. | $19.19 | 2019 | |
| Medtronic, INC. | $17.49 | 2023 | In.Pact Admiral |
| Novo Nordisk INC | $17.31 | 2024 | Ozempic, Rybelsus |
| Lexicon Pharmaceuticals, INC. | $17.29 | 2024 | |
| Alnylam Pharmaceuticals INC. | $15.14 | 2025 | Amvuttra |
| Philips North America LLC | $12.19 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Snoddy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.